NRx Pharmaceuticals (NRXP) Projected to Post Quarterly Earnings on Thursday

NRx Pharmaceuticals (NASDAQ:NRXP) is expected to be announcing its Q3 2025 results before the market opens on Thursday, November 13th. Analysts expect the company to announce earnings of ($0.08) per share and revenue of $6.8250 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Monday, November 17, 2025 at 4:30 PM ET.

NRx Pharmaceuticals (NASDAQ:NRXP) last issued its earnings results on Monday, August 18th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.67). On average, analysts expect NRx Pharmaceuticals to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

NRx Pharmaceuticals Trading Down 2.9%

Shares of NRXP opened at $2.66 on Thursday. The business’s 50 day moving average is $3.02 and its 200 day moving average is $2.85. The company has a market capitalization of $52.69 million, a PE ratio of -1.19 and a beta of 1.76. NRx Pharmaceuticals has a 12-month low of $1.12 and a 12-month high of $6.01.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on NRXP shares. BTIG Research reaffirmed a “buy” rating on shares of NRx Pharmaceuticals in a research note on Monday, August 25th. D. Boral Capital reaffirmed a “buy” rating and issued a $34.00 price objective on shares of NRx Pharmaceuticals in a research note on Tuesday, October 21st. Zacks Research raised NRx Pharmaceuticals to a “hold” rating in a research note on Wednesday, September 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research note on Wednesday, October 8th. Finally, Ascendiant Capital Markets lifted their price objective on NRx Pharmaceuticals from $46.00 to $47.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, NRx Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $34.75.

Hedge Funds Weigh In On NRx Pharmaceuticals

A hedge fund recently raised its stake in NRx Pharmaceuticals stock. Geode Capital Management LLC increased its stake in shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) by 27.9% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 172,255 shares of the company’s stock after purchasing an additional 37,598 shares during the quarter. Geode Capital Management LLC owned 1.00% of NRx Pharmaceuticals worth $562,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 4.27% of the company’s stock.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.